New HIV vaccine candidate moves to human safety testing
NCT ID NCT05423418
First seen Feb 17, 2026 · Last updated May 22, 2026 · Updated 22 times
Summary
This study tested an experimental HIV vaccine in 65 healthy, HIV-negative adults to see if it is safe and triggers an immune response. Participants received three shots over two months, each with a different dose of an immune-boosting ingredient called ALFQ. The goal was to find the safest and most effective dose for future studies.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HUMAN IMMUNODEFICIENCY VIRUS (HIV) are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Walter Reed Army Institute of Research, Clinical Trials Center
Silver Spring, Maryland, 20910, United States
Conditions
Explore the condition pages connected to this study.